Mathematical framework for activity-based cancer biomarkers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 41, 2015, Pages 12627-12632

  Kwong, Gabriel A ^a,b,e   Dudani, Jaideep S ^a,b   Carrodeguas, Emmanuel ^a,b   Mazumdar, Eric V ^a,b   Zekavat, Seyedeh M ^a,b   Bhatia, Sangeeta N ^a,b,c,d  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Activity based probes; Cancer diagnostics; Compartmental modeling; Nanomedicine; Urine biomarkers

Indexed keywords

BIOLOGICAL MARKER; PROTEINASE; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER DIAGNOSIS; COMPARTMENT MODEL; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME STABILITY; MATHEMATICAL MODEL; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; HUMAN; METABOLISM; MOLECULAR IMAGING; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PROCEDURES;

ANIMALS; BIOMARKERS, TUMOR; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MOLECULAR IMAGING; NANOMEDICINE; NEOPLASMS, EXPERIMENTAL;

EID: 84944088971     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1506925112     Document Type: Article

References (41)

1. Sawyers CL (2008) The cancer biomarker problem. Nature 452(7187):548-552.
2. La Thangue NB, Kerr DJ (2011) Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 8(10):587-596.
3. Kwong GA, et al. (2013) Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol 31(1):63-70.
4. Hori SS, Gambhir SS (2011) Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci Transl Med 3(109):109ra116.
5. Lutz AM, Willmann JK, Cochran FV, Ray P, Gambhir SS (2008) Cancer screening: A mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med 5(8):e170.
6. Zheng G, Patolsky F, Cui Y, Wang WU, Lieber CM (2005) Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol 23(10):1294-1301.
7. Bunimovich YL, et al. (2006) Quantitative real-time measurements of DNA hybridization with alkylated nonoxidized silicon nanowires in electrolyte solution. J Am Chem Soc 128(50):16323-16331.
8. Nam JM, Thaxton CS, Mirkin CA (2003) Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301(5641):1884-1886.
9. Hauck TS, Giri S, Gao Y, Chan WC (2010) Nanotechnology diagnostics for infectious diseases prevalent in developing countries. Adv Drug Deliv Rev 62(4-5):438-448.
10. Gaster RS, et al. (2009) Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat Med 15(11):1327-1332.
11. Decuzzi P, Ferrari M (2008) Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 29(3):377-384.
12. D'Souza AL, et al. (2009) A strategy for blood biomarker amplification and localization using ultrasound. Proc Natl Acad Sci USA 106(40):17152-17157.
13. Ronald JA, Chuang HY, Dragulescu-Andrasi A, Hori SS, Gambhir SS (2015) Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker. Proc Natl Acad Sci USA 112(10):3068-3073.
14. Edgington LE, Verdoes M, Bogyo M (2011) Functional imaging of proteases: Recent advances in the design and application of substrate-based and activity-based probes. Curr Opin Chem Biol 15(6):798-805.
15. Hilderbrand SA, Weissleder R (2010) Near-infrared fluorescence: Application to in vivo molecular imaging. Curr Opin Chem Biol 14(1):71-79.
16. Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12):1421-1434.
17. Thurber GM, Schmidt MM, Wittrup KD (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29(2):57-61.
18. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ (2012) Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 503:255-268.
19. Hauert S, Berman S, Nagpal R, Bhatia SN (2013) A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. Nano Today 8(6):566-576.
20. Zuckerman JE, Choi CH, Han H, Davis ME (2012) Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci USA 109(8):3137-3142.
21. Lin KY, Kwong GA, Warren AD, Wood DK, Bhatia SN (2013) Nanoparticles that sense thrombin activity as synthetic urinary biomarkers of thrombosis. ACS Nano 7(10):9001-9009.
22. Warren AD, Kwong GA, Wood DK, Lin KY, Bhatia SN (2014) Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics. Proc Natl Acad Sci USA 111(10):3671-3676.
23. Warren AD, et al. (2014) Disease detection by ultrasensitive quantification of microdosed synthetic urinary biomarkers. J Am Chem Soc 136(39):13709-13714.
24. Danino T, et al. (2015) Programmable probiotics for detection of cancer in urine. Sci Transl Med 7(289):289ra84.
25. Choi HS, et al. (2007) Renal clearance of quantum dots. Nat Biotechnol 25(10):1165-1170.
26. Bremer C, Tung CH, Weissleder R (2001) In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7(6):743-748.
27. Turk BE, Huang LL, Piro ET, Cantley LC (2001) Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol 19(7):661-667.
28. Seltzer JL, et al. (1990) Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. J Biol Chem 265(33):20409-20413.
29. Schroeder A, et al. (2012) Treating metastatic cancer with nanotechnology. Nat Rev Cancer 12(1):39-50.
30. Harisinghani MG, et al. (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348(25):2491-2499.
31. Heesakkers RAM, et al. (2009) Prostate cancer: Detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology 251(2):408-414.
32. Kummar S, et al.; Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT) (2009) Phase 0 clinical trials: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 45(5):741-746.
33. Lokich J, Ellenberg S, Gerson B, Knox WE, Zamcheck N (1984) Plasma clearance of carcinoembryonic antigen following hepatic metastatectomy. J Clin Oncol 2(5):462-465.
34. Locker GY, et al.; ASCO (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313-5327.
35. Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A (2005) Liver metastases of colorectal cancer: US, CT or MR? Cancer Imaging 5 (Spec No A):S149-156.
36. Wang AZ, Langer R, Farokhzad OC (2012) Nanoparticle delivery of cancer drugs. Annu Rev Med 63:185-198.
37. Hawkins MJ, Soon-Shiong P, Desai N (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60(8):876-885.
38. Liotta LA, et al. (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284(5751):67-68.
39. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
40. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141(1):52-67.
41. Park JH, et al. (2009) Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 5(6):694-700.